EloraTZP Phase 2b Results (2026): Eloralintide + Tirzepatide Weight Loss and HbA1c Data
EloraTZP Phase 2b: eloralintide plus tirzepatide cut weight 23.3% at 48 weeks vs 14.8% for tirzepatide alone in T2D. Full dose table and CagriSema context.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
EloraTZP, the investigational combination of the amylin receptor agonist eloralintide and the GIP/GLP-1 receptor agonist tirzepatide, produced up to 23.3% mean weight reduction at 48 weeks in a Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, according to results Eli Lilly released on September 30, 2026 and presented at EASD 2026. This post sets out the full dose table, how the combination compares with tirzepatide alone, how it sits next to the cagrilintide-plus-semaglutide (CagriSema) data in type 2 diabetes, the tolerability trade-off, and what comes next.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: In Lilly's 48-week Phase 2b trial in adults with type 2 diabetes and obesity or overweight, EloraTZP (eloralintide 9 mg plus tirzepatide 15 mg) reduced body weight by 23.3% versus 14.8% with tirzepatide 15 mg alone and 3.0% with placebo, with HbA1c falling by up to 2.9 points; adverse-event discontinuation was higher with the combination (10.8% to 27.0%).
TL;DR:
- EloraTZP pairs a selective amylin receptor agonist (eloralintide) with a dual GIP/GLP-1 receptor agonist (tirzepatide), both given once weekly.
- Highest-dose arm: -23.3% body weight and -2.9 HbA1c points at 48 weeks (efficacy estimand), versus -14.8% and -2.4 for tirzepatide 15 mg.
- Results are sponsor-reported Phase 2b data and are not yet peer-reviewed; the trial enrolled only people with type 2 diabetes.
- Discontinuation due to adverse events ranged from 10.8% to 27.0% across combination arms, versus 2.9% for tirzepatide alone.
- Lilly plans a Phase 3 program for a co-formulated product by the end of 2026; eloralintide monotherapy is already in Phase 3.
| Item | EloraTZP (Phase 2b) | Tirzepatide 15 mg (same trial) | CagriSema (REDEFINE 2) |
|---|---|---|---|
| Developer | Eli Lilly | Eli Lilly | Novo Nordisk |
| Mechanism | Amylin + GIP/GLP-1 | GIP/GLP-1 | Amylin + GLP-1 |
| Population | Obesity/overweight + T2D | Obesity/overweight + T2D | Obesity/overweight + T2D |
| Duration | 48 weeks | 48 weeks | 68 weeks |
| Best mean weight change | -23.3% | -14.8% | -13.7% (treatment-policy) |
| Dosing interval | Once weekly (two injections in trial) | Once weekly | Once weekly |
| Stage | Phase 2b; Phase 3 planned | Approved (separate indications) | Phase 3 completed |
What was announced
Lilly's September 30, 2026 release described a randomized, placebo-controlled Phase 2b study in 367 adults with obesity or overweight and type 2 diabetes. Mean baseline HbA1c was 8.1%. Participants received one of several combinations of eloralintide and tirzepatide, eloralintide alone, tirzepatide 15 mg alone, or placebo for 48 weeks. The figures below are the efficacy estimand, which estimates the effect had participants stayed on treatment.
| Arm (48 weeks) | Weight change | HbA1c change |
|---|---|---|
| Eloralintide 9 mg + tirzepatide 15 mg | -23.3% | -2.9 |
| Eloralintide 6 mg + tirzepatide 10 mg | -19.9% | -2.6 |
| Eloralintide 6 mg + tirzepatide 5 mg | -19.4% | -2.7 |
| Eloralintide 3 mg + tirzepatide 5 mg | -13.2% | -2.2 |
| Tirzepatide 15 mg | -14.8% | -2.4 |
| Eloralintide 3 mg | -8.2% | -1.1 |
| Eloralintide 6 mg | -12.3% | -1.4 |
| Eloralintide 9 mg | -11.1% | -1.3 |
| Placebo | -3.0% | -0.3 |
Two details stand out for researchers reading the table. First, eloralintide 6 mg plus tirzepatide 5 mg (-19.4%) exceeded tirzepatide 15 mg alone (-14.8%), which suggests the amylin component adds effect even at a low incretin dose. Second, eloralintide monotherapy plateaued between 6 mg and 9 mg in this diabetic population, while the combination continued to scale with tirzepatide dose.
Eloralintide: mechanism and evidence base
Eloralintide (LY3841136) is a long-acting peptide agonist selective for the amylin receptor, a complex of the calcitonin receptor with receptor activity-modifying proteins (RAMPs). Amylin signalling acts on hindbrain satiety centres and slows gastric emptying, a pathway distinct from incretin receptor agonism. The 48-week Phase 2 monotherapy trial in adults with obesity without diabetes reported mean weight reductions up to about 20% and is published as PMID 41207310, "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial" (The Lancet, 2025).
The smaller monotherapy effect in the EloraTZP trial (up to 12.3%) is consistent with a long-observed pattern: weight-reduction agents tend to produce less weight loss in people with type 2 diabetes than in people without it. For a direct comparison with the other selective long-acting amylin analogues, see the eloralintide vs cagrilintide comparison and the petrelintide pairing below.
Tirzepatide: the comparator arm
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Its reference trial in the same population is SURMOUNT-2 (NCT04657003), in which once-weekly tirzepatide 10 mg and 15 mg were studied for 72 weeks in adults with obesity or overweight and type 2 diabetes, with mean weight reduction of about 15% at the higher dose: PMID 37385275, "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)" (The Lancet, 2023). The -14.8% seen with tirzepatide 15 mg at 48 weeks in the EloraTZP trial sits close to that benchmark, which gives some confidence that the comparator arm behaved as expected. A mechanism overview is in the tirzepatide mechanism post.
How EloraTZP compares with CagriSema in type 2 diabetes
The closest prior amylin-plus-incretin dataset is CagriSema, the co-administration of cagrilintide with semaglutide. Because EloraTZP was tested only in type 2 diabetes, the fairer reference is REDEFINE 2 rather than REDEFINE 1.
| Trial | Population | Duration | Mean weight change | Source |
|---|---|---|---|---|
| EloraTZP Phase 2b | Obesity + T2D | 48 wk | Up to -23.3% (efficacy) | Lilly release, Sep 30, 2026 |
| REDEFINE 2 (CagriSema) | Obesity + T2D | 68 wk | -13.7% vs -3.4% placebo (treatment-policy) | PMID 40544432 |
| REDEFINE 1 (CagriSema) | Obesity, no T2D | 68 wk | -20.4% vs -3.0% placebo | PMID 40544433 |
These are indirect, cross-trial comparisons. The trials differ in duration, phase, size, estimand, and dose-escalation design, so the numbers cannot be read as a head-to-head result. What they do show is that adding an amylin agonist to a stronger incretin backbone (dual GIP/GLP-1 rather than GLP-1 alone) produced the largest weight reduction yet reported in a type 2 diabetes obesity population. A third approach, a single molecule with both amylin and GLP-1 activity, is amycretin, covered in PMID 39626360.
The tolerability trade-off
Discontinuation due to adverse events ranged from 10.8% to 27.0% across the EloraTZP arms, compared with 0% to 10.8% for eloralintide alone, 2.9% for tirzepatide alone, and 16.7% for placebo. The unusually high placebo figure makes the numbers harder to interpret, and Lilly has not yet published a full breakdown by event type. Gastrointestinal effects are the expected class effect for both amylin and incretin agonists, and the dose-escalation scheme in a Phase 3 co-formulation will likely be designed around this signal. Researchers tracking dosing intervals and pharmacokinetics across the class can use the peptide half-life chart.
Regulatory status and what's next
| Compound | Status (October 2026) |
|---|---|
| EloraTZP | Investigational; Phase 3 of a co-formulation planned to start by end of 2026 |
| Eloralintide | Investigational; Phase 3 monotherapy program ongoing |
| Tirzepatide | FDA-approved for type 2 diabetes, chronic weight management, and obstructive sleep apnea |
| CagriSema | Investigational; regulatory decision expected Q4 2026 per sponsor |
Neither eloralintide nor EloraTZP is approved by the FDA or EMA, and timelines in sponsor releases may change. Upcoming registrations can be followed in the clinical trial tracker. Peer-reviewed publication of the Phase 2b results has not yet been announced; this page will be updated with a PMID once one is indexed.
Cited studies
- PMID 41207310, "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial" (The Lancet, 2025). https://doi.org/10.1016/S0140-6736(25)02155-5
- PMID 37385275: "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial" (The Lancet, 2023). https://doi.org/10.1016/S0140-6736(23)01200-X
- PMID 40544432: "Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes" (REDEFINE 2; NEJM, 2025). https://doi.org/10.1056/NEJMoa2502082
- PMID 40544433, "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity" (REDEFINE 1; NEJM, 2025). https://doi.org/10.1056/NEJMoa2502081
- PMID 39626360: "Subcutaneous amycretin versus semaglutide 2.4 mg in adults with overweight or obesity: a randomised, double-blind, double-dummy, phase 1b/2 trial" (The Lancet, 2025). https://doi.org/10.1016/S0140-6736(24)02496-8
- Eli Lilly press release, September 30, 2026: https://www.biospace.com/press-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes
Frequently asked questions
Q: What is EloraTZP?
A: EloraTZP is Eli Lilly's investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP/GLP-1 receptor agonist. In the Phase 2b trial the two were given as separate once-weekly injections, and Lilly plans to study a co-formulated version in Phase 3.
Q: How much weight loss did EloraTZP show in Phase 2?
A: The highest-dose arm (eloralintide 9 mg plus tirzepatide 15 mg) reported 23.3% mean weight reduction at 48 weeks versus 3.0% with placebo, using the efficacy estimand. All participants had type 2 diabetes, a population in which weight reduction is typically smaller.
Q: Is EloraTZP better than tirzepatide alone?
A: In the same trial, tirzepatide 15 mg alone produced 14.8% weight reduction and a 2.4-point HbA1c reduction, compared with 23.3% and 2.9 points for the top combination arm. The combination also had higher adverse-event discontinuation, so the trial shows greater efficacy with a tolerability cost rather than a simple improvement.
Q: How does EloraTZP compare with CagriSema?
A: In type 2 diabetes, REDEFINE 2 reported 13.7% weight reduction with CagriSema at 68 weeks (treatment-policy estimand), while EloraTZP reported up to 23.3% at 48 weeks (efficacy estimand). The trials used different designs and estimands, so any comparison is indirect.
Q: When could EloraTZP be approved?
A: EloraTZP is still investigational. Lilly has said a Phase 3 program for a co-formulation is planned to start by the end of 2026, and Phase 3 obesity programs usually take several years before a regulatory submission.
See also:
- EASD 2026: Amylin and Incretin Peptide Data, Research Roundup: all sponsor readouts from the same conference week
- Eloralintide vs Cagrilintide: the two leading selective amylin analogues compared
- Petrelintide vs Eloralintide: the third long-acting amylin analogue against Lilly's candidate
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.